¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

»ï¼º¼­¿ïº´¿ø ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ-´ëÇÑÀü¸³¼±ÇÐȸ-ºñ´¢±â°è±âÃÊÀÇÇבּ¸È¸°øµ¿½ÉÆ÷Áö¾ö : 2019-01-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
»ï¼º¼­¿ïº´¿ø ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ-´ëÇÑÀü¸³¼±ÇÐȸ-ºñ´¢±â°è±âÃÊÀÇÇבּ¸È¸°øµ¿½ÉÆ÷Áö¾ö : 2019-01-19
±³À°ÀÏÀÚ : 2019-01-19
±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ¾Ïº´¿ø B1 ´ë°­´ç  
±³À°ÁÖÁ¦ : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ-´ëÇÑÀü¸³¼±ÇÐȸ-ºñ´¢±â°è±âÃÊÀÇÇבּ¸È¸°øµ¿½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574  
À̸ÞÀÏ : app@app2010.com      
±³À°Á¾·ù : ºñ´¢±â°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í »çÀüµî·Ï 2¸¸¿ø, ÇöÀåµî·Ï 3¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 01-19  08:30~08:50 Registration  () 
±âŸ 01-19  08:50~09:00 Opening remark , Ãà»ç  () 
±³À°½Ã°£ 01-19  09:00~09:20 Critical roles of hMAGEA2 in prostate cancer and development of cancer animal model  ¹Ú¼Û(DGIST) 
±³À°½Ã°£ 01-19  09:20~09:40 Identification of novel biomarkers for diagnosis of metastatic prostate cancer  ÀÌ»ó±Ô(°æºÏ´ë ¾à´ë) 
±³À°½Ã°£ 01-19  09:40~10:00 Expression of AR-V7 in urine derived exosomal RNA and development of CRPC  ±¸ÀÚÀ±(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 01-19  10:00~10:20 Feasibility of ctDNA analysis in prostate cancer  Á¶¿µ³²(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 01-19  10:20~10:40 ctDNA to predict prognosis of prostate cancer  Á¶ÀºÇØ(³ì½ÊÀÚÁö³ð) 
È޽Ġ01-19  10:40~11:00 Coffee break  () 
±³À°½Ã°£ 01-19  11:00~11:20 Medical travel among non-Seoul residents to seek prostate cancer treatment in medical facilities of Seoul  ±èÀçÇå(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 01-19  11:20~11:40 National practice patterns and medical costs for prostate cancer in Korea across a 10 year periods  °­È£¿ø(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 01-19  11:40~12:00 Lifestyle risk prediction model for prostate cancer in a Korean population  ±è¼ºÇÑ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 01-19  12:00~12:20 Surgical simulation in Urology  °í¿µÈÖ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 01-19  12:20~12:40 Digital health and future technology  À̰Ǹí(ÃæºÏ´ëÇб³) 
±âŸ 01-19  12:40~12:40 Closing remark  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û »õº´µ¿ °Ç¸³±â³ä ºÎõ¼º¸ðº´¿ø ¾È¼¾ÅÍ ½ÉÆ÷Áö¾ö(ºÎõ½Ã ¾È°úÀÇ»çȸ) : 2019-01-21
´ÙÀ½±Û ´ëÇÑ¿Ü°úÇÐȸ ÃÖ¼Òħ½ÀÀû À¯¹æ»ý°Ë ½ÉÆ÷Áö¾ö : 2019-01-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20904 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 18 2024-05-28
20903 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 21 2024-05-28
20902 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 26 2024-05-28
20901 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 20 2024-05-28
20900 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 13 2024-05-28
20899 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 17 2024-05-28
20898 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 7 2024-05-28
20897 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 18 2024-05-28
20896 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 15 2024-05-28
20895 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 10 2024-05-28
20894 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 14 2024-05-28
20893 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 12 2024-05-28
20892 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 33 2024-05-28
20891 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 123 2024-05-27
20890 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 43 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷